Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Attovia Therapeutics, Inc. announced that its management team will participate in three upcoming investor conferences in November 2026.

Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026

Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that

Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday

U.S. stocks mostly fell, but Quanex surged 16.6% after beating earnings and sales estimates; Reading, BBCP, Astera Labs and others also gained.

8-K filing — Attovia Therapeutics, Inc. (ATTO)

Filed: 2026-09-02 AccNo: 0001193125-26-380215 Size: 388 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K

Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(4.88) per share which missed the analyst consensus estimate of $(4.62) by 5.63 percent. This is a 31.54 percent decrease over losses of $(3.71) per share

Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30